Purpose: The purpose of the study is to evaluate the effectiveness of risk minimiza- (GePaRD) and 84% (EpiChron), and concurrent use of high-dose cilostazol and potent CYP3A4/CYP2C19 inhibitors decreased between 6% (Sweden) and 100% (EpiChron).
| INTRODUCTION
Cilostazol is a platelet aggregation inhibitor approved in Europe in 2002 to improve walking distances in patients with intermittent claudication. Cilostazol has been associated with spontaneous reports of serious bleeding and cardiovascular effects including heart attacks, angina, and arrhythmias. The European Medicines Agency (EMA) evaluated the benefits and risks of cilostazol in a referral and recommended implementation of risk minimization measures to restrict the use of cilostazol to patients that could benefit from treatment and in which important risks are minimized. 1 Risk minimization measures included labeling changes (Table 1 ) and educational communications directed to health care professionals through the Otsuka Europe website and "Dear Doctor" letters implemented in 2013.
To evaluate the impact of these risk minimization measures, we compared the prevalence of cilostazol use and of the conditions targeted by these risk minimization measures before and after these measures were implemented.
| METHODS

| Data sources
The study was conducted in The Health Improvement Network (THIN), UK [2] [3] [4] ; the EpiChron cohort (EpiChron) from the Aragon Institute of Health Sciences (IACS), Aragon, Spain 5, 6 ; the Information System for Research in Primary Care (SIDIAP), Catalonia, Spain 7 ; the Swedish National Registers 8, 9 ; and the German Pharmacoepidemiological Research Database (GePaRD). 10 The main features of the study databases are presented in Table S1 , online supporting information. The baseline characteristics of users of cilostazol before implementation of risk minimization measures have been published elsewhere. 
| Study population
New users of cilostazol were identified before and after implementation of risk minimization measures ( Figure 1 ). The period before implementation was from the date cilostazol became available in each country through September 14, 2012 in THIN; December 31, 2012
in EpiChron, SIDIAP, and Sweden; and December 31, 2011 in GePaRD. Data for the year 2012 were not available in GePaRD at the time of the baseline assessment. 11 The period after implementation was the year 2014. New users were defined as patients who received a first-ever prescription of cilostazol during each study period after having at least 6 months of continuous enrollment in the database. The date of the first cilostazol prescription was defined as the start date. Patients with a recorded prescription of cilostazol at any time before the start date were excluded. New users were followed from the start date until the first of the following: end of enrollment in the database, death, or end of the study period.
| Evaluation of the effectiveness of risk minimization measures
We compared the prevalence of new users of cilostazol and the frequency of conditions targeted by risk minimization measures included in the labeling (Table 1) 
KEY POINTS
• This study evaluated the effectiveness of risk minimization measures among new users of cilostazol in the United Kingdom, Spain, Sweden, and Germany.
• The observed decrease in the prevalence of cilostazol use, cardiovascular contraindications, and concurrent use of 2 or more antiplatelet drugs or interacting medications indicates that the risk minimization measures were effective in all the study populations.
• Stopping smoking before initiating cilostazol remains an area of improvement, as prevalence of smoking after risk minimization measures decreased in only 1 of 4 study populations where smoking was evaluated.
were unstable angina pectoris and recent myocardial infarction or coronary intervention. We also evaluated the prevalence of contraindications in the labeling before implementation of labeling changes (ie, old In GePaRD, a twice-daily dosage was also assumed. In SIDIAP, evaluation of daily dose was not conducted, as information on dosage instructions was not available. Medical diagnoses and use of medications were ascertained through the coding system specific to each database (Table S1 , online supporting information).
| Analysis
The annual prevalence of cilostazol use was calculated in each data- 
| Prevalence and patterns of use
We included 22 593 and 1821 new users of cilostazol before and after implementation of risk minimization measures, respectively ( Table 2 ). 
| Comorbidity and comedications
The most frequent comorbidities and comedications before and after implementation of risk minimization measures are presented in Tables   TABLE 2 Characteristics and patterns The terms before and after refer to the periods before and after the implementation of risk minimization measures. (Table S4 , online supporting information).
| Evaluation of the effectiveness of risk minimization measures
Results of the assessment of the risk minimization measures are presented in Table 3 
| DISCUSSION
In this study, we evaluated the effectiveness of risk minimization measures for the use of cilostazol in the UK, Spain, Sweden, and Germany.
The study addressed the concerns raised during the EMA Article 31 cilostazol referral and the requirement to evaluate the risk minimization measures through drug utilization studies. The characteristics of new users of cilostazol remained similar before and after implementation of risk minimization activities. In both periods, there was a higher proportion of men than women, and most users were elderly and had a high prevalence of comorbidity, especially cardiovascular disease, and concurrent use of other medications. In general, the risk minimization measures were effective in all study populations, as indi- in Spain. 15 In that study, most users were elderly and had a high prevalence of comorbidity and use of comedications.
A strength of our study is the use of automated health databases, The terms before and after refer to the periods before and after the implementation of risk minimization periods.
CI, confidence interval; EpiChron, EpiChron cohort from Aragon Health Sciences Institute (IACS); GePaRD, German Pharmacoepidemiological Research Database; NA, not available; RR, rate ratio; SIDIAP, Information System for the Improvement of Research in Primary Care; THIN, The Health Improvement Network; UK, United Kingdom.
a Current smoking at the start date. In Sweden, smoking was evaluated only through smoking-related diagnoses and dispensations for smoking-cessation drugs.
b Percentage of users with at least 1 visit to a specialist (vascular surgery, cardiology, diabetology) 2 to 4 months after the start date.
c Discontinuation of cilostazol within the first 3 months of treatment.
d Unstable angina pectoris and myocardial infarction or coronary intervention within the last 6 months.
e Rate ratio of visits to the general practitioner or specialist between users with and without increased risk of serious cardiac events (arrhythmias, hypotension, or coronary heart disease). In GePaRD, visits were expressed as the number of diagnoses per patient-year of continuous use, because only the first visit to the same physician is recorded during a quarter. Results from this study can be generalized to each respective country. The THIN database includes information for approximately 6% of the UK population, and the population covered in the database has been shown to have demographics, deprivation index, disease prevalence, and mortality rates similar to the overall UK population. 3 In Spain, EpiChron covers all the primary care practices of the public health system in the region of Aragon, and SIDIAP covers about 80% of those in the region of Catalonia. 17, 18 In Sweden, data included in the study involve the entire population. In Germany, the data cov- • Alexandra Prados-Torres, Beatriz Poblador-Plou, Francisca
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